Log in

OTCMKTS:NEVPF - NeuroVive Pharmaceutical Stock Price, Forecast & News

-0.01 (-3.54 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: $0.15
50-Day Range
MA: $0.16
52-Week Range
Now: $0.15
Volume3,800 shs
Average Volume5,063 shs
Market Capitalization$7.85 million
P/E RatioN/A
Dividend YieldN/A
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual SalesN/A
Book Value$0.21 per share


Net Income$-7,870,000.00


Market Cap$7.85 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive NEVPF News and Ratings via Email

Sign-up to receive the latest news and ratings for NEVPF and its competitors with MarketBeat's FREE daily newsletter.

NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Frequently Asked Questions

What is NeuroVive Pharmaceutical's stock symbol?

NeuroVive Pharmaceutical trades on the OTCMKTS under the ticker symbol "NEVPF."

When is NeuroVive Pharmaceutical's next earnings date?

NeuroVive Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for NeuroVive Pharmaceutical.

Has NeuroVive Pharmaceutical been receiving favorable news coverage?

Media coverage about NEVPF stock has trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NeuroVive Pharmaceutical earned a news impact score of 1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for NeuroVive Pharmaceutical.

Who are some of NeuroVive Pharmaceutical's key competitors?

What other stocks do shareholders of NeuroVive Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroVive Pharmaceutical investors own include Allena Pharmaceuticals (ALNA), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP), Ardelyx (ARDX), ArQule (ARQL) and Athersys (ATHX).

Who are NeuroVive Pharmaceutical's key executives?

NeuroVive Pharmaceutical's management team includes the folowing people:
  • Mr. Erik Kinnmann M.D., Ph.D., M.B.A., Assoc. Prof., Chief Exec. Officer (Age 61)
  • Ms. Catharina Jz Johansson, CFO & VP of Investor Relations (Age 52)
  • Dr. Eskil Elmér, Chief Scientific Officer & VP of Discovery (Age 49)
  • Daniel Schale, Director of Communications
  • Dr. Magnus Hansson, Chief Medical Officer and VP of Preclinical & Clinical Devel. (Age 43)

How do I buy shares of NeuroVive Pharmaceutical?

Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NeuroVive Pharmaceutical's stock price today?

One share of NEVPF stock can currently be purchased for approximately $0.15.

How big of a company is NeuroVive Pharmaceutical?

NeuroVive Pharmaceutical has a market capitalization of $7.85 million. The company earns $-7,870,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. NeuroVive Pharmaceutical employs 7 workers across the globe.View Additional Information About NeuroVive Pharmaceutical.

What is NeuroVive Pharmaceutical's official website?

The official website for NeuroVive Pharmaceutical is http://www.neurovive.com/.

How can I contact NeuroVive Pharmaceutical?

NeuroVive Pharmaceutical's mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The company can be reached via phone at 46-4-627-562-20 or via email at [email protected]

MarketBeat Community Rating for NeuroVive Pharmaceutical (OTCMKTS NEVPF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about NeuroVive Pharmaceutical and other stocks. Vote "Outperform" if you believe NEVPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEVPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel